Signal
FDA rejects Replimune's melanoma therapy for the second time
Evidence first: scan the strongest sources, then decide whether to go deeper.
Published 2026-04-13 08:20 UTCUpdated 2026-04-13 14:28 UTC
rss
clinical_trialsfdadrug_developmentsafety_signals
Source links open
Source links and full evidence are open here. Archive history, compare-over-time, alerts, exports, API, integrations, and workflow are paid.
No card needed for the free brief.
Evidence trail (top sources)
top sources (2 domains)domains are deduped. counts indicate coverage, not truth.2 top sources shown
limited source diversity in top sources
Overview
Replimune has faced a major regulatory hurdle as the FDA rejected its melanoma immunotherapy candidate RP1 for the second time. The initial refusal occurred in July of the previous year, and despite efforts to address the agency's concerns, the resubmitted application was again declined. This repeated rejection highlights the challenges Replimune faces in advancing RP1 through the regulatory process and may impact the therapy's development timeline and market prospects.
Score total
1.01
Momentum 24h
2
Posts
2
Origins
2
Source types
1
Duplicate ratio
0%
Why now
- The second FDA rejection occurred recently, underscoring ongoing regulatory hurdles.
- Resubmission efforts by Replimune have not yet overcome FDA concerns.
- The decision affects current clinical development and potential market entry plans.
Why it matters
- Repeated FDA rejection signals challenges in advancing Replimune's melanoma therapy.
- Regulatory setbacks may impact the biotech's development timeline and strategy.
- Highlights the stringent FDA requirements for immunotherapy approvals.
LLM analysis
Topic mix: lowPromo risk: lowSource quality: medium
Recurring claims
- The FDA has rejected Replimune's melanoma immunotherapy candidate RP1 twice, first in July and again after resubmission.
How sources frame it
- Fierce Pharma And Pharmaphorum: neutral
This update reflects the latest regulatory setback for Replimune's RP1 therapy as reported by multiple biotech news sources.
All evidence
All evidence
The second time is not the charm for Replimune’s melanoma candidate RP1. After spurning the immunotherapy last July, the FDA has now rejected the biotech’s resubmitted application.
Fierce Pharma (All) · fiercepharma.com · 2026-04-13 14:28 UTC
FDA hands another rejection to Replimune's melanoma therapy
pharmaphorum · pharmaphorum.com · 2026-04-13 08:20 UTC
Show filters & breakdown
Posts loaded: 0Publishers: 2Origin domains: 2Duplicates: -
Showing 2 / 0
Top publishers (this list)
- Fierce Pharma (All) (1)
- pharmaphorum (1)
Top origin domains (this list)
- fiercepharma.com (1)
- pharmaphorum.com (1)